Glucagonoma

1. Clinical Overview

Summary

Glucagonoma is a rare functioning pancreatic neuroendocrine tumour (PNET) arising from glucagon-secreting alpha (α) cells of the pancreatic islets of Langerhans. [1,2] It is characterised by the classic Glucagonoma Syndrome, typically presenting with the memorable "4 Ds":

1. Dermatosis – Necrolytic Migratory Erythema (NME)
2. Diabetes Mellitus – usually mild to moderate
3. Deep Vein Thrombosis – hypercoagulable state
4. Depression – neuropsychiatric manifestations

Additional hallmark features include severe weight loss, glossitis, stomatitis, angular cheilitis, and normocytic anaemia. [2,3]

Necrolytic Migratory Erythema (NME) is virtually pathognomonic for glucagonoma, occurring in 70-90% of cases. [4] This distinctive, migratory, blistering erythematous rash predominantly affects the perineum, groin, buttocks, lower abdomen, and perioral region. It is often misdiagnosed for years as eczema, psoriasis, or intertrigo before the correct diagnosis is established. [5]

Glucagonomas are typically large tumours (> 4-6 cm diameter) at diagnosis, with the majority located in the pancreatic tail or body (60-80%). [6] Critically, 60-80% of patients have metastatic disease (liver, lymph nodes) at presentation, making glucagonoma one of the more aggressive functional PNETs. [7] Despite this, the tumours are often slow-growing, and median survival with metastatic disease is 3-5 years with appropriate treatment. [8]

Diagnosis rests on demonstrating markedly elevated fasting plasma glucagon levels (typically > 500 pg/mL, often > 1000 pg/mL), with normal levels less than 100 pg/mL. [9] Imaging with contrast-enhanced CT or MRI localises the primary tumour, while 68Ga-DOTATATE PET-CT provides superior staging for somatostatin receptor-positive disease. [10]

Management depends on disease stage:

• Localised disease: Surgical resection (distal pancreatectomy ± splenectomy) offers potential cure
• Metastatic disease: Somatostatin analogues (octreotide, lanreotide) for symptom control and anti-tumour effect; peptide receptor radionuclide therapy (PRRT), targeted therapy (everolimus, sunitinib), or cytotoxic chemotherapy for progressive disease
• Universal measures: DVT prophylaxis/treatment with anticoagulation, zinc supplementation, nutritional support, skin care [1,6]

Clinical Pearls

The "4 Ds" Mnemonic: Dermatosis (NME), Diabetes, DVT, Depression. This classic exam mnemonic is essential for rapid recall of glucagonoma syndrome.

Necrolytic Migratory Erythema is Pathognomonic: Any patient with unexplained, migratory, blistering erythematous rash affecting the perineum, groin, or lower extremities should have serum glucagon measured. The rash may precede other features by years.

Usually Large and Malignant: Unlike insulinomas (which are typically small and benign), glucagonomas are usually > 4 cm and have metastasised by the time of diagnosis. This reflects their indolent growth and non-specific early symptoms.

Hypoaminoacidaemia and Zinc Deficiency: The pathogenesis of NME is thought to involve hypoaminoacidaemia (from glucagon-driven gluconeogenesis consuming amino acids) and zinc deficiency. Both amino acid infusions and zinc supplementation may improve the rash. [11]

Thromboembolic Risk is Critical: DVT/PE occurs in 30-50% of patients and represents a major cause of morbidity and mortality. All patients require thromboprophylaxis (typically LMWH), and many require therapeutic anticoagulation. [12]

MEN1 Association: Approximately 3-5% of glucagonomas occur as part of Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome. Screen for family history, hyperparathyroidism, and pituitary adenomas. [13]

---

2. Epidemiology

Incidence and Prevalence

Glucagonoma is an extremely rare tumour, representing one of the rarest functioning PNETs:

Tumour Characteristics at Diagnosis

Geographic and Ethnic Distribution

• No significant geographic or ethnic variation documented
• Reported worldwide, though case series are predominantly from Europe and North America due to rarity

Associations and Risk Factors

Exam Detail: Exam Focus: The extreme rarity of glucagonoma makes it a high-yield exam topic, as it tests pattern recognition of the pathognomonic syndrome. Be prepared to:

1. Recognise the "4 Ds" mnemonic
2. Identify NME from description or image
3. Know diagnostic glucagon threshold (> 500 pg/mL)
4. Understand why tumours are usually large and metastatic at diagnosis (slow growth, non-specific symptoms until syndrome develops)
5. Compare with insulinoma (small, benign, hypoglycaemia) vs glucagonoma (large, malignant, hyperglycaemia)

---

3. Aetiology and Pathophysiology

Tumour Origin and Biology

Cellular Origin

Glucagonomas arise from pancreatic islet alpha (α) cells, which constitute approximately 15-20% of normal islet cell mass and are responsible for glucagon secretion. [14] Alpha cells are more concentrated in the pancreatic tail, explaining the predominant tumour location.

Normal Physiology of Glucagon:

• Secreted in response to hypoglycaemia, fasting, and stress
• Promotes hepatic glycogenolysis (glycogen breakdown) and gluconeogenesis (glucose synthesis from amino acids, lactate, glycerol)
• Stimulates lipolysis and ketogenesis
• Inhibited by insulin, glucose, and somatostatin

Genetic and Molecular Features

Pathophysiology of Glucagonoma Syndrome

The constellation of clinical features results from chronic glucagon excess, leading to a sustained catabolic state:

1. Hyperglycaemia and Diabetes Mellitus

Mechanism:

• Glucagon stimulates hepatic glycogenolysis and gluconeogenesis
• Increases hepatic glucose output
• Results in mild-to-moderate fasting and postprandial hyperglycaemia [2]

Clinical Features:

• Diabetes develops in 70-90% of patients
• Usually mild (fasting glucose 7-15 mmol/L)
• Often manageable with oral hypoglycaemics or low-dose insulin
• Rarely causes severe hyperglycaemia or ketoacidosis (residual insulin secretion persists)

2. Necrolytic Migratory Erythema (NME)

Mechanism (Multifactorial): [4,5,11]

Histopathology of NME:

• Superficial epidermal necrolysis with pallor and vacuolisation of upper epidermis
• Subcorneal or intraepidermal cleft formation
• Psoriasiform acanthosis (thickening of lower epidermis)
• Perivascular lymphocytic infiltrate
• Non-specific but characteristic pattern

Clinical Course:

• Erythematous patches → vesicles/bullae → erosions → crusting → central healing with peripheral extension → migratory pattern
• May wax and wane over months to years
• Often improves rapidly with treatment (somatostatin analogues, surgery)

3. Venous Thromboembolism (VTE)

Mechanism: [12]

• Glucagon may directly activate coagulation pathways
• Endothelial dysfunction and increased tissue factor expression
• Associated thrombocytosis in some cases
• General paraneoplastic hypercoagulability

Clinical Significance:

• DVT/PE occurs in 30-50% of patients
• May be presenting feature
• Major cause of morbidity and mortality
• Requires lifelong anticoagulation in many cases

4. Weight Loss and Cachexia

Mechanism:

• Catabolic state: Increased protein breakdown (muscle wasting), lipolysis
• Amino acids diverted to hepatic gluconeogenesis
• Anorexia (multifactorial: tumour, depression, malnutrition)
• Malabsorption in some cases

Clinical Features:

• Weight loss in 60-80% of patients
• Often severe (> 10% of body weight)
• Muscle wasting, temporal wasting
• May mimic malignancy-associated cachexia

5. Neuropsychiatric Manifestations

Mechanism:

• Poorly understood; may relate to amino acid depletion, zinc deficiency, chronic illness
• Possible direct central effects of glucagon or other co-secreted peptides

Clinical Features:

• Depression (20-40%)
• Apathy, lethargy
• Cognitive impairment
• Emotional lability

6. Stomatitis, Glossitis, Angular Cheilitis

Mechanism:

• Zinc deficiency
• Hypoaminoacidaemia
• Mucosal epithelial dysfunction (similar to skin in NME)

Clinical Features:

• Painful, red, swollen tongue (glossitis)
• Oral ulceration, stomatitis
• Cracking at corners of mouth (angular cheilitis)
• May precede or accompany NME

7. Normocytic Anaemia

Mechanism:

• Multifactorial: chronic disease, malnutrition, possible bone marrow suppression
• Often mild-to-moderate

8. Diarrhoea

Mechanism:

• Direct effect of glucagon on gut motility
• Co-secretion of other peptides
• Occurs in 15-30% of cases

Exam Detail: Viva Question: "Why does glucagonoma cause necrolytic migratory erythema?"

Model Answer: "Chronic glucagon excess drives gluconeogenesis, which consumes amino acids, leading to hypoaminoacidaemia. This, combined with zinc and essential fatty acid deficiencies secondary to the catabolic state, impairs epidermal integrity and wound healing. The epidermis undergoes superficial necrolysis and psoriasiform hyperplasia, manifesting as the characteristic migratory, blistering rash. Zinc supplementation and amino acid infusions may improve the rash, supporting this mechanism."

---

4. Clinical Presentation

Classic Glucagonoma Syndrome: The "4 Ds" (and Beyond)

The glucagonoma syndrome is one of the most distinctive paraneoplastic endocrine syndromes in medicine. While the "4 Ds" mnemonic is useful, the full clinical picture is broader:

Detailed Description of Necrolytic Migratory Erythema (NME)

NME is the hallmark feature of glucagonoma and warrants detailed understanding:

Evolution of Lesions

Stages of NME:

1. Erythematous patch: Ill-defined area of erythema
2. Vesiculation/bullae: Superficial blisters develop
3. Erosion: Blisters rupture, leaving denuded skin
4. Crusting: Serous crusts form over erosions
5. Central healing: Centre begins to re-epithelialise
6. Peripheral extension: Active erythematous border expands outward → annular/arcuate pattern
7. Migration: Process repeats in new locations

Time course: Each lesion evolves over 7-14 days; new lesions appear while old ones heal → migratory pattern

Distribution

Classic sites (high-friction, intertriginous areas):

• Perineum and groin (most common)
• Buttocks and lower abdomen
• Inner thighs
• Perioral region (around mouth)
• Lower extremities

Less common: Trunk, distal extremities (hands/feet usually spared)

Differential Diagnosis of NME

NME can be mimicked by other conditions causing similar cutaneous findings:

Temporal Presentation

Typical timeline:

1. Rash appears first (NME) – often 1-3 years before diagnosis
2. Misdiagnosed as eczema, psoriasis, fungal infection, or nutritional deficiency
3. Systemic symptoms develop: Weight loss, diabetes, glossitis
4. DVT/PE may occur
5. Diagnosis finally made when glucagon level checked (often after dermatologist or endocrinologist recognises pattern)

Delayed diagnosis is common: Median time from symptom onset to diagnosis is 2-8 years in many series. [5]

Examination Findings

General Inspection:

• Cachectic appearance, muscle wasting, temporal wasting
• Pallor (anaemia)

Skin:

• NME lesions as described
• Thin, fragile skin
• Hyperpigmentation in healed areas

Oral Cavity:

• Glossitis: red, beefy, swollen tongue
• Angular cheilitis
• Stomatitis, oral ulceration

Cardiovascular:

• May have signs of DVT (unilateral leg swelling, warmth, erythema)

Abdominal:

• Usually no palpable mass (tumour retroperitoneal)
• Hepatomegaly if liver metastases (uncommon to be palpable)

Neurological:

• Cognitive slowing, flat affect (depression)

Exam Detail: Exam Scenario (MRCP PACES or Viva):

Stem: "This 55-year-old woman presents with a 2-year history of a migratory blistering rash affecting her groin and lower abdomen, unintentional 15 kg weight loss, and new-onset diabetes. She was recently treated for a DVT. What is the most likely diagnosis?"

Expected Answer: "The combination of necrolytic migratory erythema, diabetes, weight loss, and DVT is pathognomonic for glucagonoma syndrome. I would confirm the diagnosis with fasting serum glucagon (expecting > 500 pg/mL) and imaging to identify a pancreatic mass and stage the disease."

Follow-up Question: "How would you manage her DVT risk?"

Expected Answer: "Glucagonoma is associated with a hypercoagulable state. She requires therapeutic anticoagulation for the acute DVT (typically LMWH or DOAC), and given the underlying malignancy and persistent elevated glucagon, she will likely require long-term anticoagulation. I would also ensure appropriate DVT prophylaxis perioperatively if she undergoes surgical resection."

---

5. Investigations

Diagnostic Algorithm

SUSPECTED GLUCAGONOMA SYNDROME
(NME + Diabetes + Weight Loss ± DVT)
              ↓
      BIOCHEMICAL CONFIRMATION
      - Fasting Serum Glucagon
      - Fasting Glucose / HbA1c
      - Chromogranin A
      - FBC, UEC, LFT
      - Zinc, Amino Acid Profile
              ↓
   POSITIVE (Glucagon > 500 pg/mL)
              ↓
      TUMOUR LOCALISATION
      - CT Abdomen (Pancreas Protocol)
      - MRI Abdomen (alternative)
              ↓
      STAGING & FUNCTIONAL IMAGING
      - 68Ga-DOTATATE PET-CT
      - Assess liver metastases
      - Assess nodal involvement
              ↓
   MEN1 SCREENING (if indicated)
      - Serum Calcium, PTH
      - Prolactin, IGF-1
      - Family history
      - Genetic testing
              ↓
   HISTOLOGICAL CONFIRMATION
      - Usually clinical + biochemical diagnosis sufficient
      - Biopsy if atypical or metastatic disease requiring tissue diagnosis

Biochemical Investigations

Interpretation Pearls

Glucagon > 500 pg/mL is diagnostic in the presence of clinical syndrome and pancreatic mass. Levels are often > 1000 pg/mL and may reach 10,000 pg/mL in advanced cases. [9]

False elevations: Renal failure, sepsis, prolonged fasting, familial hyperglucagonaemia (very rare, no tumour). Always correlate with clinical and imaging findings.

Chromogranin A is useful for monitoring treatment response and detecting recurrence but is not specific for glucagonoma.

Imaging Investigations

Anatomical Imaging

Typical Imaging Features:

• Large size (median 5-7 cm; rarely less than 2 cm)
• Pancreatic tail/body location (60-80%)
• Hypervascular on arterial phase
• Liver metastases in 60-80%
• Lymph node metastases less common

Functional Imaging

Utility of DOTATATE PET-CT:

• Confirms somatostatin receptor expression (predicts response to somatostatin analogues and PRRT)
• Superior staging (detects occult metastases)
• Treatment planning (PRRT candidacy)

Histopathology

Skin Biopsy (NME)

Indication: Not required for diagnosis if clinical features and biochemistry are classic; may be performed if NME presentation is atypical

Histological Findings:

• Superficial epidermal necrolysis with pallor and vacuolisation of keratinocytes in upper epidermis
• Subcorneal or intraepidermal cleft formation
• Psoriasiform acanthosis (thickening of lower epidermis)
• Perivascular lymphocytic infiltrate
• Non-specific but characteristic pattern; similar findings can occur in zinc deficiency and essential fatty acid deficiency

Tumour Biopsy

Indications:

• Atypical presentation requiring histological confirmation
• Metastatic disease requiring tissue diagnosis before systemic therapy
• EUS-FNA for primary tumour or percutaneous liver biopsy for metastases

Histological Findings:

• Neuroendocrine architecture (trabecular, nested, gyriform patterns)
• Immunohistochemistry:
  • Glucagon positive (confirms glucagon-secreting tumour)
  • Chromogranin A positive (general neuroendocrine marker)
  • Synaptophysin positive (neuroendocrine marker)
  • "Ki-67 proliferation index: Usually less than 20% (G1-G2 grade) [8]"

WHO Grading (2019):

• G1: Ki-67 less than 3%
• G2: Ki-67 3-20%
• G3: Ki-67 > 20% (less common in glucagonoma)

Summary of Key Investigations

First-line:

1. Fasting serum glucagon (diagnostic)
2. CT abdomen (localisation and staging)
3. 68Ga-DOTATATE PET-CT (functional staging)

Supportive: 4. Chromogranin A 5. Zinc, amino acids 6. FBC, glucose, HbA1c 7. MEN1 screening if indicated

Exam Detail: Viva Question: "What is the diagnostic threshold for serum glucagon in glucagonoma?"

Model Answer: "The diagnostic threshold is fasting serum glucagon > 500 pg/mL in the presence of clinical features and a pancreatic mass. Normal levels are less than 100 pg/mL. In glucagonoma, levels are often > 1000 pg/mL and may exceed 10,000 pg/mL in advanced disease. It's important to exclude false elevations from renal failure, sepsis, or prolonged fasting by correlating with clinical context and imaging."

---

6. Management

Management Overview

Management of glucagonoma is multifaceted, addressing:

1. Tumour control (surgical resection, medical therapy)
2. Symptom control (somatostatin analogues, skin care, nutrition)
3. Complication management (anticoagulation for VTE, diabetes management)
4. Surveillance and follow-up

Management Algorithm

                  GLUCAGONOMA CONFIRMED
         (Glucagon > 500 pg/mL + Pancreatic Mass)
                          ↓
              STAGING (CT/MRI + DOTATATE PET)
                          ↓
       ┌──────────────────┴──────────────────┐
       │                                     │
   LOCALISED DISEASE                 METASTATIC DISEASE
   (No liver/nodal mets)             (Liver/nodal mets)
       │                                     │
       ↓                                     ↓
   RESECTABLE?                       ASSESS TUMOUR BURDEN
       │                                     │
    YES │                          ┌─────────┴─────────┐
       ↓                           │                   │
SURGICAL RESECTION           LIMITED BURDEN      EXTENSIVE BURDEN
(Distal Pancreatectomy ±         (less than 25% liver)        (> 25% liver)
 Splenectomy)                     │                   │
       │                           ↓                   ↓
       ↓                    SOMATOSTATIN         SOMATOSTATIN
PRE-OP PREPARATION          ANALOGUES (SSA)      ANALOGUES (SSA)
- Octreotide 100 μg          (Octreotide LAR         +
  TDS SC for 1-2 weeks       or Lanreotide)      SYSTEMIC THERAPY
- Nutritional support             │                   │
- DVT prophylaxis            DOTATATE PET      ┌─────┴─────┐
- Zinc supplementation       POSITIVE?         │           │
       │                           │        PRRT      TARGETED Rx
       ↓                    ┌──────┴──────┐  (177Lu-   (Everolimus,
   SURGERY                  │             │  DOTATATE)  Sunitinib)
   ↓                      YES            NO      or
CURATIVE INTENT               │             │    Chemotherapy
   ↓                          ↓             ↓   (Temozolomide
POST-OP SURVEILLANCE    PRRT (Peptide   Everolimus    + Capecitabine)
- Clinical                 Receptor      Sunitinib         │
- Glucagon levels          Radionuclide  or Chemo          ↓
- CT/MRI 3-6 monthly       Therapy)           │        REASSESS
  for 2 years, then             │             │        RESPONSE
  annually                      ↓             ↓        3-monthly
- DOTATATE PET if      REASSESS RESPONSE  REASSESS         │
  recurrence suspected     3-6 monthly    RESPONSE    PROGRESS?
                                │             │            │
                              STABLE/     PROGRESS?    CHANGE Rx
                              RESPONSE        │
                                              ↓
                                        LIVER-DIRECTED
                                          THERAPY?
                                        (Embolisation,
                                         Ablation)

ALL PATIENTS REGARDLESS OF STAGE:
────────────────────────────────────
✓ Anticoagulation (LMWH/DOAC) for DVT prophylaxis/treatment
✓ Zinc supplementation (50-100 mg elemental Zn daily)
✓ Nutritional support (high-protein diet, amino acid infusions if severe)
✓ Skin care (emollients, wound care for NME lesions)
✓ Diabetes management (oral hypoglycaemics, insulin)
✓ MEN1 screening (if young age, family history)
✓ Psychological support (depression management)

Surgical Management

Indications for Surgery

Curative intent:

• Localised disease without distant metastases
• Resectable primary tumour
• Debulking in selected cases with limited metastatic disease (for symptom control)

Surgical Approaches

Perioperative Management

Preoperative Optimisation (1-2 weeks):

• Somatostatin analogue: Octreotide 100 μg TDS SC to reduce glucagon levels and improve symptoms
• Nutritional support: High-protein diet, oral supplements; parenteral nutrition if severe malnutrition
• Zinc supplementation: 50-100 mg elemental zinc daily
• DVT prophylaxis: LMWH (enoxaparin 40 mg daily SC)
• Diabetes optimisation: Glycaemic control
• Skin care: Treat secondary infections in NME lesions

Intraoperative:

• Continue DVT prophylaxis (pneumatic compression devices)
• Monitor glucose (may improve acutely post-resection)

Postoperative:

• Monitor for pancreatitis, pancreatic fistula (common after distal pancreatectomy)
• Continue LMWH for at least 28 days post-surgery (high VTE risk)
• Monitor glucagon levels (should normalise within days if complete resection)
• Watch for diabetes resolution or improvement (may reduce insulin requirements)

Outcomes of Surgery

Medical Management

Somatostatin Analogues (SSA)

First-line medical therapy for symptom control and tumour growth control. [1,6]

Clinical Effects:

• Reduces serum glucagon by 50-70%
• Improves NME in 70-80% (often within 2-4 weeks)
• Improves weight, nutritional status
• Anti-tumour effect: Stabilises disease in 40-60% (median PFS 14-18 months) [6]
• Does not cure but provides excellent symptom control

Adverse Effects:

• GI: Nausea, diarrhoea/steatorrhoea (bile salt malabsorption), abdominal cramps
• Biliary: Gallstones, biliary sludge (monitor with ultrasound)
• Glucose: May worsen hyperglycaemia (suppresses insulin more than glucagon in some patients)
• Injection site reactions

Peptide Receptor Radionuclide Therapy (PRRT)

Indication: Progressive metastatic disease with positive DOTATATE PET scan

Dose: 4 cycles of 7.4 GBq IV every 8 weeks

Adverse Effects: Myelosuppression, nephrotoxicity (co-administer amino acid infusion for renal protection)

Targeted Molecular Therapy

Indication: Progressive metastatic disease; second-line after SSA failure

Choice: Either can be used; choice depends on comorbidities, patient preference

Cytotoxic Chemotherapy

Indication: Progressive high-grade (G3) or refractory disease

Liver-Directed Therapy

Indication: Liver-dominant metastatic disease with limited extrahepatic disease

Outcomes: Symptomatic improvement in 60-80%; PFS 12-18 months

Supportive and Adjunctive Management

Anticoagulation (Critical)

Indication: All patients with glucagonoma due to 30-50% VTE risk [12]

Monitoring: Clinical signs of VTE; D-dimer if suspicion

Zinc Supplementation

Rationale: Zinc deficiency contributes to NME [11]

Dose: 50-100 mg elemental zinc PO daily (e.g., zinc sulphate 220 mg = 50 mg elemental Zn)

Effect: May improve NME within 2-4 weeks; often used adjunctively with SSA

Nutritional Support

Goal: Reverse catabolic state, improve NME

Effect: May improve NME, weight, quality of life

Skin Care

NME-specific:

• Emollients: Barrier creams, moisturisers
• Wound care: Non-adherent dressings for erosions
• Antibiotics: If secondary bacterial infection (common)
• Avoid irritants: Gentle cleansers, avoid friction

Effect: Symptomatic relief; reduces secondary infection

Diabetes Management

Approach: Standard diabetes care; usually mild hyperglycaemia

Note: Diabetes often improves after surgical resection or effective SSA therapy as glucagon levels fall

MEN1 Screening and Management

Indication: Glucagonoma in patient less than 40 years, family history of endocrine tumours, or multiple PNETs

Screening:

• Serum calcium, PTH (primary hyperparathyroidism)
• Prolactin, IGF-1 (pituitary adenoma)
• Imaging for other PNETs (gastrinoma, insulinoma, non-functioning)
• Genetic testing for MEN1 mutation (menin gene)

If MEN1 confirmed: Lifelong surveillance for additional tumours; family counselling; genetic testing of first-degree relatives

Follow-Up and Surveillance

Post-Surgical (Curative Resection)

Monitoring:

• Fasting glucagon at 1, 3, 6, 12 months, then annually
• CT/MRI abdomen at 3, 6, 12 months, then annually for 5 years
• 68Ga-DOTATATE PET if glucagon rises or CT suspicious for recurrence
• Chromogranin A every 3-6 months

Recurrence: 30-40% at 5 years; usually hepatic metastases

Metastatic Disease (Medical Management)

Monitoring:

• Clinical assessment every 3 months (symptoms, weight, NME)
• Fasting glucagon, CgA every 3 months
• CT/MRI abdomen every 3-6 months (RECIST criteria)
• 68Ga-DOTATATE PET annually or if progression suspected

Treatment adjustment: Escalate therapy if progression on imaging or biochemistry

Exam Detail: Viva Question: "A patient with metastatic glucagonoma on octreotide LAR 30 mg monthly develops progressive liver metastases on CT after 18 months of stable disease. What are the next treatment options?"

Model Answer:

1. DOTATATE PET scan: If positive (which is likely given previous response to octreotide), the patient is a candidate for peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. This has shown significant PFS benefit in SSTR-positive NETs.

2. Targeted therapy: If PRRT is not available or DOTATATE PET is negative, I would consider everolimus (mTOR inhibitor) or sunitinib (tyrosine kinase inhibitor), both of which have shown PFS benefit in progressive PNETs.

3. Liver-directed therapy: If disease is liver-dominant with limited extrahepatic disease, options include transarterial embolisation (TAE/TACE) or selective internal radiation therapy (SIRT).

4. Chemotherapy: If high-grade features or refractory to above, consider temozolomide + capecitabine (CAPTEM).

Throughout, I would continue supportive measures: anticoagulation, zinc, nutritional support, and skin care for NME."

---

7. Complications

Tumour-Related Complications

Treatment-Related Complications

---

8. Prognosis and Outcomes

Survival by Stage

Prognostic Factors

Favourable:

• Localised disease (no metastases)
• Complete surgical resection (R0)
• Low Ki-67 (less than 3%, G1)
• DOTATATE PET-positive (predicts SSA/PRRT response)
• Good response to somatostatin analogues

Unfavourable:

• Liver metastases (> 25% liver involvement)
• High Ki-67 (> 20%, G3)
• Progressive disease despite SSA
• Poor performance status

Functional Outcomes

Quality of Life

• Significantly impaired at diagnosis due to NME, weight loss, systemic symptoms
• Markedly improves with effective treatment (surgery or SSA)
• Chronic management (SSA injections, anticoagulation, surveillance) impacts QoL but generally well-tolerated

---

9. Prevention and Screening

Primary Prevention

Not applicable: Glucagonoma is a sporadic tumour in > 95% of cases; no known environmental or dietary risk factors

Secondary Prevention (Early Detection)

MEN1 Families:

• Genetic testing for MEN1 mutation carriers
• Surveillance from age 5-10 years (annual biochemistry, imaging every 1-3 years)
• Early detection of PNETs allows potentially curative surgery before metastasis

General Population:

• No screening programme (too rare)
• High index of suspicion for unexplained NME → measure serum glucagon

---

10. Evidence and Guidelines

Key Guidelines

Landmark Evidence

---

11. Patient and Layperson Explanation

What is a Glucagonoma?

A glucagonoma is a very rare tumour in the pancreas that makes too much of a hormone called glucagon. Glucagon is normally used by the body to raise blood sugar levels when they are too low. When a tumour makes too much glucagon all the time, it causes a collection of symptoms called glucagonoma syndrome.

What are the Symptoms?

The main symptoms are:

1. A distinctive skin rash (called necrolytic migratory erythema or NME): This is a red, blistering rash that appears on the groin, buttocks, and lower body. It moves around the body and can look like eczema or psoriasis. This rash is the most recognisable sign of glucagonoma.

2. Weight loss: Most people lose a lot of weight without trying.

3. Diabetes: High blood sugar levels develop, usually mild.

4. Blood clots: There is an increased risk of blood clots in the legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism).

5. Sore mouth and tongue: The tongue can become red, swollen, and painful.

6. Feeling low or depressed.

How is it Diagnosed?

Your doctor will:

• Take a blood test to measure glucagon levels. In glucagonoma, levels are very high (> 500 pg/mL; normal is less than 100).
• Do a CT or MRI scan to find the tumour in the pancreas.
• Do a special nuclear medicine scan (DOTATATE PET scan) to see if the cancer has spread.

How is it Treated?

If the tumour has not spread:

• Surgery to remove the tumour (and sometimes part of the pancreas and spleen) is the best treatment and can be curative.

If the tumour has spread (metastatic):

• Injections (called somatostatin analogues, like octreotide or lanreotide) are given once a month to lower glucagon levels and control symptoms. These often make the rash go away within a few weeks.
• Targeted therapy (everolimus or sunitinib) or radioactive treatment (PRRT) may be used if the tumour grows despite injections.
• Chemotherapy is used for more aggressive tumours.

Other important treatments:

• Blood thinners to prevent blood clots (very important)
• Zinc tablets to help the skin rash
• High-protein diet and nutritional supplements to gain weight
• Skin care for the rash

What is the Outlook?

• If the tumour can be removed completely with surgery, many people are cured or live for many years without problems.
• If the tumour has spread, it cannot be cured, but treatment can control symptoms and slow the tumour's growth. Many people live 5-7 years or longer with good quality of life on treatment.

Key Takeaways

• Glucagonoma is very rare but recognisable by the characteristic rash and symptoms.
• Blood tests and scans confirm the diagnosis.
• Surgery is the best treatment if possible; injections control symptoms if the cancer has spread.
• Blood clot prevention is essential.
• With treatment, symptoms often improve dramatically, and many people live for years.

---

12. References

Primary Sources

1. Mallinson CN, Bloom SR, Warin AP, et al. A glucagonoma syndrome. Lancet. 1974;2(7871):1-5. PMID: 4134233.

2. van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151(5):531-537. PMID: 15538929.

3. Menon G, Maynard CK. Glucagonoma. StatPearls [Internet]. 2025 Jan. PMID: 30137784.

4. Foss MG, Murphy-Chutorian B, Steger KA. Necrolytic Migratory Erythema. StatPearls [Internet]. 2025 Jan. PMID: 30422467.

5. Tolliver S, Graham J, Kaffenberger BH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Int J Dermatol. 2018;57(6):642-645. doi: 10.1111/ijd.13947. PMID: 29450880.

6. Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41(2):bnz004. doi: 10.1210/endrev/bnz004. PMID: 31555796. [Note: ENETS 2023 guidance reference: Hofland J, Kaltsas G, de Herder WW, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. doi: 10.1111/jne.13318. PMID: 37578384.]

7. Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012;26(6):737-753. doi: 10.1016/j.bpg.2012.12.003. PMID: 23582916.

8. Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011;36(1):35-43. doi: 10.3109/07435800.2010.525085. PMID: 21226566.

9. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2(3):347-361. PMID: 6268399.

10. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709. [NETTER-1 trial]

11. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2(3):347-361. PMID: 6268399. [Pathophysiology review]

12. John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016;30(12):2016-2022. doi: 10.1111/jdv.13752. PMID: 27324238. [VTE risk discussion]

13. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. doi: 10.1210/jc.2012-1230. PMID: 22723327.

14. Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039-1048. doi: 10.1210/en.2011-1499. PMID: 22166985. [Glucagon physiology]

15. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523. doi: 10.1056/NEJMoa1009290. PMID: 21306238. [RADIANT-3 trial; also summarises targeted therapy and chemotherapy options]

16. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513. doi: 10.1056/NEJMoa1003825. PMID: 21306237. [SUN-111 trial]

17. Zhang M, Zhao P, Shi B, et al. Clinical experience in diagnosis and treatment of glucagonoma syndrome. Hepatobiliary Pancreat Dis Int. 2004;3(3):473-475. PMID: 15313692.

18. Popoviciu MS, Kaka N, Sethi Y, et al. Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities. Int J Mol Sci. 2023;24(16):12676. doi: 10.3390/ijms241612676. PMID: 37628857. [Secondary diabetes in glucagonoma]

---

13. Examination Focus

High-Yield Exam Topics

Glucagonoma is a classic exam case due to its pathognomonic syndrome and visual recognition (NME rash). Expect to be tested on:

1. Recognition of the "4 Ds" (Dermatosis, Diabetes, DVT, Depression)
2. Identification of NME from description or photograph
3. Diagnostic criteria (glucagon > 500 pg/mL)
4. Comparison with other functional PNETs (especially insulinoma)
5. Management principles (surgery vs SSA)
6. VTE risk and need for anticoagulation

Common Exam Questions (MCQ/SBA)

Question 1: A 58-year-old woman presents with a 6-month history of a migratory blistering rash affecting her groin and buttocks, 12 kg weight loss, and new-onset diabetes. Blood tests show Hb 105 g/L, glucose 12 mmol/L, HbA1c 8.2%. What is the single most appropriate next investigation?

A. Skin biopsy
B. Fasting serum glucagon
C. CT abdomen
D. Serum zinc
E. Anti-tissue transglutaminase antibodies

Answer: B. Fasting serum glucagon

Rationale: The clinical syndrome (NME + diabetes + weight loss) is pathognomonic for glucagonoma. The diagnostic test is fasting serum glucagon (expect > 500 pg/mL). CT abdomen would follow to localise the tumour.

---

Question 2: A patient with confirmed glucagonoma and liver metastases is started on octreotide LAR. Which of the following is the most important concurrent medication?

A. Metformin
B. Zinc supplementation
C. Anticoagulation
D. Proton pump inhibitor
E. Pancreatic enzyme replacement

Answer: C. Anticoagulation

Rationale: VTE occurs in 30-50% of glucagonoma patients and is a major cause of morbidity/mortality. All patients require DVT prophylaxis (LMWH or DOAC). Zinc is helpful but not as critical as anticoagulation.

---

Viva Scenarios

Scenario 1: Clinical Presentation

Examiner: "This is a photograph of a patient's groin area showing erythematous, erosive lesions with central healing. The patient also has diabetes and recent DVT. What is your diagnosis?"

Candidate: "This appearance is consistent with necrolytic migratory erythema (NME), which, combined with diabetes and DVT, suggests glucagonoma syndrome. NME is pathognomonic for glucagonoma, a rare pancreatic neuroendocrine tumour secreting excess glucagon."

Examiner: "How would you confirm the diagnosis?"

Candidate: "I would measure fasting serum glucagon—levels > 500 pg/mL are diagnostic. I would also perform contrast-enhanced CT of the abdomen to localise the tumour, which is typically large (> 4 cm) and located in the pancreatic tail. 68Ga-DOTATATE PET-CT would assess for metastatic disease."

---

Scenario 2: Management

Examiner: "The patient has a 6 cm pancreatic tail mass with no liver metastases. What is your management plan?"

Candidate: "The patient has localised disease and is a candidate for curative surgical resection. I would perform distal pancreatectomy with splenectomy. Preoperatively, I would optimise the patient with:

• Octreotide 100 μg TDS SC to reduce glucagon and improve symptoms
• DVT prophylaxis with LMWH
• Nutritional support and zinc supplementation
• Post-splenectomy vaccinations (pneumococcus, Hib, meningococcus)

Postoperatively, I would monitor glucagon levels (should normalise within days) and perform surveillance imaging to detect recurrence."

---

Scenario 3: Pathophysiology

Examiner: "Why does glucagonoma cause necrolytic migratory erythema?"

Candidate: "NME results from the catabolic effects of excess glucagon. Glucagon drives gluconeogenesis, which consumes amino acids, leading to hypoaminoacidaemia. This, combined with zinc deficiency and essential fatty acid deficiency, impairs epidermal integrity and wound healing. The epidermis undergoes superficial necrolysis, manifesting as the characteristic migratory rash. Zinc supplementation and amino acid infusions may improve NME, supporting this mechanism."

---

Scenario 4: Differential Diagnosis

Examiner: "A patient presents with a similar rash but has no pancreatic mass and normal glucagon. What other diagnosis would you consider?"

Candidate: "The differential for NME-like rash includes:

1. Acrodermatitis enteropathica (zinc deficiency—genetic or acquired)
2. Pellagra (niacin deficiency—affects sun-exposed areas)
3. Essential fatty acid deficiency (TPN-related)

I would check serum zinc levels, nutritional history, and consider skin biopsy (shows similar histology to NME but no pancreatic mass or elevated glucagon). Treatment would be nutritional replacement."

---

Model Answers for Common Viva Questions

Q: Compare insulinoma and glucagonoma.

---

Q: What is the role of PRRT in glucagonoma?

A: "Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is indicated for progressive metastatic glucagonoma with positive 68Ga-DOTATATE PET scan (indicating somatostatin receptor expression). It delivers targeted beta-radiation to tumour cells, achieving disease stabilisation or regression. The NETTER-1 trial showed median PFS of 28 months vs 8 months with octreotide alone in midgut NETs, and this benefit is extrapolated to PNETs including glucagonoma."

---

Q: What are the main causes of morbidity and mortality in glucagonoma?

A: "The main causes are:

1. Venous thromboembolism (DVT/PE) – occurs in 30-50%; leading cause of death in some series
2. Metastatic disease – 60-80% have liver metastases at diagnosis
3. Malnutrition/cachexia – severe weight loss, hypoalbuminaemia
4. Sepsis – from secondary infection of NME lesions

Effective management includes lifelong anticoagulation, somatostatin analogues to control symptoms, nutritional support, and skin care."

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.